A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, autosomal dominant condition, classically characterised by heterotopic ossification beginning in childhood and congenital great toe malformations; occurring in response to a c.617 G>A ACVR1 mutation in the functionally important glycine/s...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Sprog: | English |
| Udgivet: |
2011
|
| _version_ | 1826282879233032192 |
|---|---|
| author | Gregson, C Hollingworth, P Williams, M Petrie, K Bullock, A Brown, M Tobias, J Triffitt, J |
| author_facet | Gregson, C Hollingworth, P Williams, M Petrie, K Bullock, A Brown, M Tobias, J Triffitt, J |
| author_sort | Gregson, C |
| collection | OXFORD |
| description | Fibrodysplasia Ossificans Progressiva (FOP) is a rare, autosomal dominant condition, classically characterised by heterotopic ossification beginning in childhood and congenital great toe malformations; occurring in response to a c.617 G>A ACVR1 mutation in the functionally important glycine/serine-rich domain of exon 6. Here we describe a novel c.587 T>C mutation in the glycine/serine-rich domain of ACVR1, associated with delayed onset of heterotopic ossification and an exceptionally mild clinical course. Absence of great toe malformations, the presence of early ossification of the cervical spine facets joints, plus mild bilateral camptodactyly of the 5th fingers, together with a novel ACVR1 mutation, are consistent with the 'FOP-variant' syndrome. The c.587 T>C mutation replaces a conserved leucine with proline at residue 196. Modelling of the mutant protein reveals a steric clash with the kinase domain that will weaken interactions with FKBP12 and induce exposure of the glycine/serine-rich repeat. The mutant receptor is predicted to be hypersensitive to ligand stimulation rather than being constitutively active, consistent with the mild clinical phenotype. This case extends our understanding of the 'FOP-variant' syndrome. © 2010. |
| first_indexed | 2024-03-07T00:50:29Z |
| format | Journal article |
| id | oxford-uuid:863ac2ea-6c2b-43c1-951f-96ca610bb337 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:50:29Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:863ac2ea-6c2b-43c1-951f-96ca610bb3372022-03-26T22:02:38ZA novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to dateJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:863ac2ea-6c2b-43c1-951f-96ca610bb337EnglishSymplectic Elements at Oxford2011Gregson, CHollingworth, PWilliams, MPetrie, KBullock, ABrown, MTobias, JTriffitt, JFibrodysplasia Ossificans Progressiva (FOP) is a rare, autosomal dominant condition, classically characterised by heterotopic ossification beginning in childhood and congenital great toe malformations; occurring in response to a c.617 G>A ACVR1 mutation in the functionally important glycine/serine-rich domain of exon 6. Here we describe a novel c.587 T>C mutation in the glycine/serine-rich domain of ACVR1, associated with delayed onset of heterotopic ossification and an exceptionally mild clinical course. Absence of great toe malformations, the presence of early ossification of the cervical spine facets joints, plus mild bilateral camptodactyly of the 5th fingers, together with a novel ACVR1 mutation, are consistent with the 'FOP-variant' syndrome. The c.587 T>C mutation replaces a conserved leucine with proline at residue 196. Modelling of the mutant protein reveals a steric clash with the kinase domain that will weaken interactions with FKBP12 and induce exposure of the glycine/serine-rich repeat. The mutant receptor is predicted to be hypersensitive to ligand stimulation rather than being constitutively active, consistent with the mild clinical phenotype. This case extends our understanding of the 'FOP-variant' syndrome. © 2010. |
| spellingShingle | Gregson, C Hollingworth, P Williams, M Petrie, K Bullock, A Brown, M Tobias, J Triffitt, J A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date |
| title | A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date |
| title_full | A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date |
| title_fullStr | A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date |
| title_full_unstemmed | A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date |
| title_short | A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date |
| title_sort | novel acvr1 mutation in the glycine serine rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date |
| work_keys_str_mv | AT gregsonc anovelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT hollingworthp anovelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT williamsm anovelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT petriek anovelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT bullocka anovelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT brownm anovelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT tobiasj anovelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT triffittj anovelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT gregsonc novelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT hollingworthp novelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT williamsm novelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT petriek novelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT bullocka novelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT brownm novelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT tobiasj novelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate AT triffittj novelacvr1mutationintheglycineserinerichdomainfoundinthemostbenigncaseofafibrodysplasiaossificansprogressivavariantreportedtodate |